On Thursday, the FDA cleared Cresilon Incs Traumagel as an emergency treatment to control moderate to severe bleeding.
The gel is expected to reach shelves later this year.
The product uses a proprietary algae-derived hydrogel technology developed by the Brooklyn-based company.
Cresilon’s Traumagel product.© Cresilon
Our proprietary hemostatic gel technology is a game-changer and unlike any other hemostatic agent currently being used.
According to the company, early results have been promising.
Scientists elsewhere have been working on their own gel-based technologies intended to improve medical care.
News from the future, delivered to your present.
